THE FIELD GUIDELooking for the eight levers? Read POSITION →

Prior work

Deep Positioning How Molecules Become Great Medicines

By Mike Rea

Positioning is not what you do to a mind. It is what you do to a product, before there is one. The argument behind POSITION: why the gap between strong science and a weak position opens in phase I and II, long before anyone writes a positioning statement.

The molecule

is the same in phase I as on the day it launches. Everything else is a decision.

  • Indication
  • Endpoint
  • Comparator
  • Segment
  • The words

Every one of those is a positioning decision, whether the people making it call it that or not.

What it argued

Five rules for shaping a product, not describing one.

The spine of the book: a manifesto for anyone who would rather decide what a medicine becomes than write a story about it later.

  1. Deep Positioning is about the product.

    Indication, dose, formulation, endpoints and the value proposition are decided early in development. Differentiation is baked into the product from the outset, not bolted on by marketers afterwards.

  2. The best time to position your drug was in phase I. The next best time is now.

    Every phase that passes without an active positioning decision is a phase in which a passive one is made for you: by precedent, by convenience, by the standard of care.

  3. Write "will become" at the top of the positioning, not "is".

    Static positioning statements are graveyards for ambition. The future-tense version is a directive: it tells the development programme what to build, and the label is the proof that it worked.

  4. Find your mechanism of value.

    The question is not "what does the drug do?" but "what is the point of your drug, to a customer?" It drives differentiation, communication, pricing and reimbursement.

  5. Don't allow people to position your drug who don't realise they're doing so.

    Indication selection, comparators, brand naming and publication plans all position a drug by accident. If a decision will change what the product is, the person making it should know they are positioning it.

Same molecule. Two teams.

The book's opening experiment: one compound, handed to two firewalled teams at the end of pre-clinical.

Team A

Takes the obvious path

  • The mechanism suggests the indication
  • The endpoint is the one used before
  • The comparator is the standard of care
  • The segment is "eligible patients"

A successful drug, on paper. And indistinguishable from the next three.

Team B

Backcasts from the market

  • Asks what the molecule is for, not what it does
  • Picks the endpoint a payer will value in five years
  • Compares against what it must really displace
  • Studies the patients who will see the difference

Same molecule. Different evidence, different label, different fight.

Both teams launched the same molecule. Only one of them launched a product anyone will remember.

  • North Star
  • Draft label
  • Backcasting cascade
  • Ifs assessment
  • Word audit
  • Mechanism framing
  • What 3 words?
  • Value proposition canvas

How it relates to POSITION

One shapes the product. The other shapes the market.

Deep Positioning decides what the product is. POSITION decides what the market will be when the product arrives. The two are sequential, but interdependent.

A brilliantly positioned drug that enters a market not ready for it will underperform. A market shaped for a drug that was not positioned for it will not buy.

FirstDeep PositioningShapes the product, in phase I and II
ThenPOSITIONShapes the market, with eight levers, before launch
Explore POSITION, the field guide

Get the book

Deep Positioning

How Molecules Become Great Medicines, by Mike Rea. For the people deciding, in phase I and II, what a medicine will become.